Global Health Ventures completes prototype manufacturing of its "X-Excite" male enhancement drug

Global Health Ventures Inc. (OTCBB:GHLV), or the "Company" a Specialty Pharma is pleased to announce today that it has completed the prototype manufacturing of the drug "X-Excite" Global's male enhancement drug. The manufacturing of the product was carried out under contract with Vida Pharma of Montreal, Canada. Vida Pharma specialized in the designing of the new tablet size, taste, and hardness. The Company has manufactured over 4000 pills from several different incipient and coatings that are all safe for human consumption. These various batches will be tested at the University of British Columbia, Canada for independent evaluation in regards to drugs adsorption, taste, color and hardness. If the samples meet our end goals then the drug will be ready for mass production under the proprietary formula for testing in humans and finally applying for regulatory approval.

The Company plans to meet the regulatory bodies in the United States, Canada and Europe to assess the time and length of the human clinical trials in the near future. The X-Excite drug is the Company's lead prescription drug. The Company is hoping to manufacture it so it can be qualified under the OTC (over the counter for pharmaceuticals) Market. If approvals are attained we believe that the product will generate a very lucrative revenue stream for Global Health.

Our lead life-style pharmaceutical product, (X-Excite), is a male sexual enhancement drug. X-Excite is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. Life style products, such as Viagra^TM, Cialis^TM and Levitra^TM, etc are highly lucrative, (nearly $5 billion) products for pharmaceutical companies. This lucrative market will continue to grow for the foreseeable future. The arrival of our new drug (X-Excite) with its fewer side effects and the rapid mode of action meets and will exceed the markets needs. The Company believes it will be able to take a lion's share of the market thus generating significant revenue for the Company.

"We are pleased that we have completed the research on this product and the manufacturing seems not to be a difficult or expensive process. With the recent successful fund raising, the Company should be able to push the approval of this product through regulatory doors". Said Dr. Salari, President and CEO.

SOURCE Global Health Ventures, Inc.